Table 1 Baseline patient demographics, disease characteristics and treatment history.
Characteristic | Intent-to-treat population | |
|---|---|---|
Age, years | n (missing) | 106 (0) |
Mean (SD) | 41.7 (9.3) | |
Median (range) | 40.2 (23-63) | |
Sex, n (%) | Male | 41 (38.7) |
Female | 65 (61.3) | |
Race, n (%) | White | 103 (97.2) |
Black | 1 (0.9) | |
Other | 2 (1.9) | |
IFN beta-1a (sc) treatment before switching to new formulation of IFN beta-1a (sc) | n (missing) | 106 (0) |
Yes | 97 (91.5) | |
No | 9 (8.5) | |
Time from first IFN beta-1a (sc) treatment, years | n (missing) | 97 (0) |
Mean (SD) | 3.76 (2.54) | |
Median (range) | 3.20 (0.4-14.8) | |
Time from first IFN beta-1a (sc) treatment, n (%) | <6 months | 3 (3.1) |
6 months-1 year | 8 (8.2) | |
1-2 years | 16 (16.5) | |
>2 years | 70 (72.2) | |
Time from first treatment with new formulation of IFN beta-1a (sc), years | n (missing) | 105 (1) |
Mean (SD) | 0.73 (0.38) | |
Median (range) | 0.61 (0.2-1.4) | |
EDSS score | n (missing) | 106 (0) |
Mean (SD) | 2.2 (1.57) | |
Median (range) | 2.0 (0.0-6.5) | |
EDSS category, n (%) | 0-<1 | 11 (10.4) |
1-<2 | 34 (32.1) | |
1-<3 | 33 (31.1) | |
3-<4 | 13 (12.3) | |
4-<5 | 6 (5.7) | |
5-<6 | 1 (0.9) | |
≥6 | 8 (7.5) |